| 98 | 4 | 54 |
| 下载次数 | 被引频次 | 阅读次数 |
目的 探究甲泼尼龙冲击治疗突发性聋过程中导致患者血压或血糖升高的影响因素。方法 纳入2021年1月至2022年12月期间应用甲泼尼龙冲击治疗的突发性聋患者188例，收集患者临床基本资料，记录治疗过程中患者血压及血糖水平，分析甲泼尼龙导致突发性聋患者血压或血糖升高的影响因素。运用Kaplan-Meier曲线分析住院期间患者不良反应发生情况。结果 188例患者中共有68例（36.17%）患者出现血压或血糖升高，20例患者判定为与甲泼尼龙很可能相关，48例患者判定为可能相关。多因素分析结果显示，年龄较大、双侧突发性聋及合并使用地塞米松进行鼓膜内注射给药是突发性聋患者血压或血糖升高的危险因素（P <0.05）。进一步分析发现，血糖升高的影响因素和血压升高的影响因素相同。Kaplan-Meier分析结果显示，合并使用地塞米松的患者、双侧突聋的患者血压或血糖水平升高的概率较高（P <0.05）。结论 甲泼尼龙冲击治疗会影响突发性聋患者的血压或血糖水平，年龄、突聋部位及是否合并使用地塞米松可能是甲泼尼龙冲击治疗导致患者血压或血糖升高的影响因素。
Abstract：AIM To explore the factors contributing to the increase in blood pressure or fasting glucose levels in patients with sudden hearing loss treated with methylprednisolone. METHODS A total of 188 patients treated with methylprednisolone for sudden hearing loss in a hospital from January 2021 to December 2022 were included in this study. Clinical characteristics were collected, blood pressure and fasting glucose levels were recorded, and the factors that contribute to the increase in blood pressure and fasting glucose levels in these patients were recorded. KaplanMeier curves were used to describe the incidence of adverse reactions during hospitalization. RESULTS A total of 188patients were included in this study, of whom 68 patients(36.17%) exhibited elevated levels of blood pressure or fasting glucose, 20 patients were assessed as very likely related to methylprednisolone, and 48 patients as possibly related.The multifactorial analysis showed that increased age, bilateral sudden hearing loss, and concurrent intratympanic dexamethasone injections were significant risk factors for the elevation of blood pressure or fasting glucose levels(P<0.05). Further research indicated that the factors influencing the increase in fasting glucose mirrored those affecting blood pressure. Kaplan-Meier analysis showed that patients using topical dexamethasone and those with bilateral sudden hearing loss had a higher likelihood of experiencing elevated blood pressure or fasting glucose levels(P<0.05).CONCLUSION Methylprednisolone pulse therapy can elevate blood pressure or fasting glucose levels in patients with sudden hearing loss. Age, the site of sudden hearing loss, and concurrent use of topical dexamethasone may be influencing factors in the elevation of blood pressure or fasting glucose levels caused by methylprednisolone pulse therapy.
[1] WU Y Z, SONG Z J, WANG Y, et al. Optimal timing of salvage intratympanic steroids in idiopathic sudden sensorineural hearing loss[J]. Laryngoscope Investig Otolaryngol, 2022, 7(5):1559.
[2] CAVALIERE M, LUCA P D, SCARPA A, et al. Combination of hyperbaric oxygen therapy and oral steroids for the treatment of sudden sensorineural hearing loss:early or late?[J]. Medicina,2022, 58(10):1421.
[3] CHAE H, LEE H S, LEE J H, et al. Usefulness of stress-related hormones as predictors and prognostic factors for idiopathic sudden sensorineural hearing loss[J]. Acta Otolaryngol, 2021,141(7):695.
[4] FRISINA R D, BAZARD P, BAUER M, et al. Translational implications of the interactions between hormones and age-related hearing loss[J]. Hear Res, 2021, 402:108093.
[5] KISHI T, WARREN-HICKS W, BAYAT N, et al. Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis[J]. Rheumatology, 2021, 60(5):2134.
[6] CHANDRASEKHAR S S, TSAI DO B S, SCHWARTZ S R, et al.Clinical practice guideline:sudden hearing loss(update)[J].Otolaryngol Head Neck Surg, 2019, 161(1_suppl):S1.
[7] HERRERA M, GARCíA BERROCAL J R, GARCíA ARUMíA, et al. Update on consensus on diagnosis and treatment of idiopathic sudden sensorineural hearing loss[J]. Acta Otorrinolaringol Esp,2019, 70(5):290.
[8] REINCKE M. Metformin:the white knight fighting corticosteroid side-effects[J]. Lancet Diabetes Endocrinol, 2020, 8(4):258.
[9] JOHNSON S, KATYAL N, NARULA N, et al. Adverse side effects associated with corticosteroid therapy:a study in 39 patients with generalized myasthenia gravis[J]. Med Sci Monit, 2021, 27:e933296.
[10] PLONTKE S K, GIRNDT M, MEISNER C, et al. Efficacy and safety of systemic, high-dose glucocorticoid therapy for idiopathic sudden sensorineural hearing loss:study protocol for athree-armed,randomized, triple-blind, multicenter trial(HODOKORT)[J].HNO, 2022, 70(Suppl 2):30.
[11]国家药品不良反应监测中心.药品不良反应报告和监测管理办法[EB/OL].(2011-07-11)[2023-8-25]. https://www.cdr-adr.org.cn/drug_1/zcfg_1/zcfg_bmgz/201702/t20170221_40428.html.
[12] YAMADA S, KITA J, SHINMURA D, et al. Update on findings about sudden sensorineural hearing loss and insight into its pathogenesis[J]. J Clin Med, 2022, 11(21):6387.
[13] KANG D W, KIM S, SUNWOO W. Correlation of neutrophil-tolymphocyte ratio and the dilation of the basilar artery with the potential role of vascular compromise in the pathophysiology of idiopathic sudden sensorineural hearing loss[J]. J Clin Med,2022, 11(19):5943.
[14] TAKEDA T, TAKEDA S, KAKIGI A. Effects of glucocorticoids on the inner ear[J]. Front Surg, 2020, 7:596383.
[15] PUDRITH C, MARTIN D, KIM Y H, et al. Glucocorticoids reduce nitric oxide concentration in middle ear effusion from lipopolysaccharide induced otitis media[J]. Int J Pediatr Otorhinolaryngol, 2010, 74(4):384.
[16] HAO W M, ZHAO L P, YU H Q, et al. Vestibular prognosis in idiopathic sudden sensorineural hearing loss with vestibular dysfunction treated with oral or intratympanic glucocorticoids:a protocol for randomized controlled trial[J]. Trials, 2020, 21(1):669.
[17] NAROZNY W, SICKO Z, PRZEWOZNY T, et al. Usefulness of high doses of glucocorticoids and hyperbaric oxygen therapy in sudden sensorineural hearing loss treatment[J]. and, 2004,25(6):916.
[18] HALEVY N, ELIAS B, SHILO S, et al. Real life safety of systemic steroids for sudden sensorineural hearing loss:a chart review[J].Eur Arch Otorhinolaryngol, 2022, 279(10):4787.
[19] ALEXANDER T H, WEISMAN M H, DEREBERY J M, et al. Safety of high-dose corticosteroids for the treatment of autoimmune inner ear disease[J]. and, 2009, 30(4):443.
[20] BEN DHAOU B, BOUSSEMA F, AYDI Z, et al. Corticoidassociated complications in elderly[J]. Tunis Med, 2012, 90(11):774.
[21] LI X, CHEN W J, XU J, et al. Clinical analysis of intratympanic injection of dexamethasone for treating sudden deafness[J]. Int J Gen Med, 2021, 14:2575.
[22] LI J, WANG J, SU Y, et al. Efficacy of high dose glucocorticoid in the salvage treatment of sudden deafness[J]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2020, 34(7):643.
[23] LIN W, XIONG G, YAN K, et al. Clinical Features and Influencing Factors for the Prognosis of Patients With Sudden Deafness[J].Front Neurol, 2022, 13:905069.
基本信息:
DOI：10.19577/j.1007-4406.2023.10.009
中图分类号:R764.437;R969
引用信息:
[1]姚斌,任倩,何锋.突发性聋患者应用甲泼尼龙冲击治疗导致血压或血糖升高的影响因素分析[J].中国临床药学杂志,2023,32(10):763-768.DOI:10.19577/j.1007-4406.2023.10.009.
2023-10-25
2023-10-25